Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City, taking place from September 12-14, 2022. In addition to the presentation, the management team will hold virtual one-on-one meetings with qualified investors. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET and accessible for 90 days on Cyclo Therapeutics' website.

Cyclo Therapeutics is focused on developing therapies for rare diseases, including Niemann-Pick Disease Type C.

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24^th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 12 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (cyclotherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol^® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005292/en/

Investor Contact:

JTC Team, LLC

Jenene Thomas

(833) 475-8247

CYTH@jtcir.com

Source: Cyclo Therapeutics, Inc.

FAQ

When will Cyclo Therapeutics present at the H.C. Wainwright conference?

Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

Who will represent Cyclo Therapeutics at the conference?

N. Scott Fine, the Chief Executive Officer of Cyclo Therapeutics, will represent the company at the conference.

Is there a way to view the presentation from Cyclo Therapeutics?

Yes, a video webcast of the Cyclo Therapeutics presentation will be available on-demand starting September 12 at 7:00 AM ET.

What is the focus of Cyclo Therapeutics?

Cyclo Therapeutics is dedicated to developing life-changing medicines for rare diseases, particularly Niemann-Pick Disease Type C.

How long will the webcast of the presentation be available?

The webcast replay will be available for 90 days following the event.